期刊文献+

HIV/AIDS vaccine development: are we walking out from the dark? 被引量:3

HIV/AIDS vaccine development: are we walking out from the dark?
原文传递
导出
摘要 The need for AIDS vaccine has been emphasized by the increase of HIV-1 prevalence in sexual transmission which bridges the spreading of HIV-1 from high-risk population to other populations. After more than two-decade intensive effort on the AIDS vaccine development, it remains elusive whether and how an effective vaccine will be achieved. Recent data released from a phase Ⅲ trial in Thailand showed a partial protection might be accomplishable by(R)the "prime-boost"combination of two vaccines: ALVAC(R) HIV vaccine (the prime), and AIDSVAX(R) B/E vaccine (the boost).1 This unprecedented large clinical trial observed that the prime-boost combination lowered the rate of HIV infection by 31.2% compared to placebo based on the modified intent-to-treat population (n=51 vs. n=74,respectively; P=0.04). However, debating on the efficacy interpretation of this trial arose among field scientists.Furthermore, how to improve the efficacy will become the most important question to be tackled. Here we reviewed the recent publications and summarized the major progress achieved. The need for AIDS vaccine has been emphasized by the increase of HIV-1 prevalence in sexual transmission which bridges the spreading of HIV-1 from high-risk population to other populations. After more than two-decade intensive effort on the AIDS vaccine development, it remains elusive whether and how an effective vaccine will be achieved. Recent data released from a phase Ⅲ trial in Thailand showed a partial protection might be accomplishable by(R)the "prime-boost"combination of two vaccines: ALVAC(R) HIV vaccine (the prime), and AIDSVAX(R) B/E vaccine (the boost).1 This unprecedented large clinical trial observed that the prime-boost combination lowered the rate of HIV infection by 31.2% compared to placebo based on the modified intent-to-treat population (n=51 vs. n=74,respectively; P=0.04). However, debating on the efficacy interpretation of this trial arose among field scientists.Furthermore, how to improve the efficacy will become the most important question to be tackled. Here we reviewed the recent publications and summarized the major progress achieved.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第23期3489-3494,共6页 中华医学杂志(英文版)
关键词 human immunodeficiency virus 1 VACCINE innate immunity cross-reactive human immunodeficiency virus 1 vaccine innate immunity cross-reactive
  • 相关文献

参考文献1

共引文献3

同被引文献19

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部